Sign inJoin waitlistJoin the waitlist

Ronald Kaufman

Professor of Urology · Albany Medical College

Credentials: · · · ·

History

Albany Medical College
Present

Brigham and Women's Hospital
1992–1993
Case Western Reserve University School of Medicine
1987–1992
Duke University Hospital
1984–1987
Case Western Reserve University School of Medicine
1983–1984
George Washington University Medical School
1979–1983

Research

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer
Clinical Cancer Research · 2003 · 425 citations
Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy
Anesthesia & Analgesia · 1998 · 242 citations
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
The Journal of Urology · 2018 · 201 citations

HF
Hugh Fisher
31 papers
Claus Roehrborn
17 papers
Bhaskar Kallakury
15 papers
Gopal Badlani
15 papers
Jeffrey Ross
15 papers
Mihir Desai
15 papers
Badar Mian
14 papers · 2 as a resident
DE
Dean Elterman
13 papers
Steven Kaplan
12 papers
EK
Eugene Kramolowsky
11 papers
KZ
Kevin Zorn
11 papers
Leo Doumanian
11 papers

Clinical trials

Trial of Void With Saline Bladder Instillation
Principal investigator · Completed
Ronald Kaufman, MD
2017–2020
Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
Principal investigator · Completed
Artivion Inc.
2015–2019
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Principal investigator · Terminated · Phase 2
Agenus Inc.
2010–2012
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Site PI · Recruiting · Phase 3
Clarity Pharmaceuticals Ltd
2023–2026